Sarah Cannon Research Institute
David R. Spigel has extensive work experience in the field of oncology. David R. began their career in 2003 at HCA Centennial Medical Center and Tennessee Oncology as a Medical Oncologist. In 2006, they joined Sarah Cannon Research Institute, where they served as an Associate Program Director and later became the Program Director for Lung Cancer. In 2016, they were promoted to the role of Chief Scientific Officer at Sarah Cannon Research Institute.
David R. Spigel completed their Bachelor of Arts (BA) degree in History from Tulane University in 1992. David R. then went on to earn their Doctor of Medicine (M.D.) from the University of Tennessee-Health Science Center College of Medicine, graduating in 1996. From 1996 to 2000, they pursued a Residency in Internal Medicine at Indiana University School of Medicine. Following that, they completed a Fellowship in Hematology/Oncology at the Dana-Farber Cancer Institute from 2000 to 2003.
Sarah Cannon Research Institute
Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. In 2022, SCRI formed a joint venture with former US Oncology Research to enhance clinical trial access and availability across the country. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted nearly 700 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA today. The combined research network brings together physicians who are actively accruing patients to clinical trials at more than 250 locations in 26 states across the US.